Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Axelsson

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
Circulation. Heart Failure|March 31, 2023
Transforming Growth Factor-β Analysis of the VANISH Trial CohortYuri Kim, Mitra Mastali, Jennifer E Van Eyk, et al.
Journal of the American College of Cardiology|July 8, 2026
Natural History of Asymptomatic Phenotypically Mild HCM: Insights From the SHaRe RegistryConstantin-Cristian Topriceanu, Iswaree Devi Balakrishnan, Christoffer Rasmus Vissing, et al.
Circulation. Heart Failure|May 9, 2025
Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical TrialConstantin-Cristian Topriceanu, Christoffer Rasmus Vissing, Anna Axelsson Raja, et al.
European Journal of Preventive Cardiology|September 20, 2022
Cholesterol not particle concentration mediates the atherogenic risk conferred by apolipoprotein B particles: a Mendelian randomization analysisAnna Helgadottir, Gudmar Thorleifsson, Audunn Snaebjarnarson, et al.
JAMA Cardiology|September 6, 2023
Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical TrialChristoffer Rasmus Vissing, Anna Axelsson Raja, Sharlene M Day, et al.
Circulation. Heart Failure|December 10, 2019
Baseline Characteristics of the VANISH CohortAnna Axelsson Raja, Ling Shi, Sharlene M Day, et al.
Nature Medicine|September 24, 2021
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trialCarolyn Y Ho, Sharlene M Day, Anna Axelsson, et al.
JAMA Cardiology|December 27, 2023
Variants at the Interleukin 1 Gene Locus and PericarditisRosa B Thorolfsdottir, Andrea B Jonsdottir, Gardar Sveinbjornsson, et al.
Nature Genetics|November 21, 2024
Genome-wide association analysis provides insights into the molecular etiology of dilated cardiomyopathySean L Zheng, Albert Henry, Douglas Cannie, et al.
Nature Genetics|March 4, 2025
Genome-wide association study meta-analysis provides insights into the etiology of heart failure and its subtypesAlbert Henry, Xiaodong Mo, Chris Finan, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Circulation. Heart Failure|March 31, 2023
Transforming Growth Factor-β Analysis of the VANISH Trial CohortYuri Kim, Mitra Mastali, Jennifer E Van Eyk, et al.
Journal of the American College of Cardiology|July 8, 2026
Natural History of Asymptomatic Phenotypically Mild HCM: Insights From the SHaRe RegistryConstantin-Cristian Topriceanu, Iswaree Devi Balakrishnan, Christoffer Rasmus Vissing, et al.
Circulation. Heart Failure|May 9, 2025
Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical TrialConstantin-Cristian Topriceanu, Christoffer Rasmus Vissing, Anna Axelsson Raja, et al.
European Journal of Preventive Cardiology|September 20, 2022
Cholesterol not particle concentration mediates the atherogenic risk conferred by apolipoprotein B particles: a Mendelian randomization analysisAnna Helgadottir, Gudmar Thorleifsson, Audunn Snaebjarnarson, et al.
JAMA Cardiology|September 6, 2023
Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical TrialChristoffer Rasmus Vissing, Anna Axelsson Raja, Sharlene M Day, et al.
Circulation. Heart Failure|December 10, 2019
Baseline Characteristics of the VANISH CohortAnna Axelsson Raja, Ling Shi, Sharlene M Day, et al.
Nature Medicine|September 24, 2021
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trialCarolyn Y Ho, Sharlene M Day, Anna Axelsson, et al.
JAMA Cardiology|December 27, 2023
Variants at the Interleukin 1 Gene Locus and PericarditisRosa B Thorolfsdottir, Andrea B Jonsdottir, Gardar Sveinbjornsson, et al.
Nature Genetics|November 21, 2024
Genome-wide association analysis provides insights into the molecular etiology of dilated cardiomyopathySean L Zheng, Albert Henry, Douglas Cannie, et al.
Nature Genetics|March 4, 2025
Genome-wide association study meta-analysis provides insights into the etiology of heart failure and its subtypesAlbert Henry, Xiaodong Mo, Chris Finan, et al.
Pageof 10